Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.
- TBS contract varied for further sample production
- Secured $200,000 unsecured loan facility with Irwin Biotech
- Revised funding arrangements with L39 Capital progressing
- July cash burn of $159,000 with $426,000 cash at hand
- Available funding supports approximately 5.5 months of operations
TBS Contract Variation Signals Product Refinement Phase
Papyrus Australia Ltd (ASX:PPY) has agreed to a variation of its contract with TBS Mining Solutions to undertake an additional sample production run. This follows a production-scale trial that met specifications on some product attributes but highlighted areas needing further development. The extension aims to incorporate this feedback and refine the biodegradable fibre board ahead of commercial-scale production.
The initial trial results underscore the iterative nature of Papyrus’s commercialisation pathway, balancing technical challenges with progress toward market readiness. The company’s Adelaide Rapid Prototyping and R&D Facility continues to play a critical role in supporting ongoing product development and pulp preparation for upcoming trials.
Funding Advances with New Loan and Capital Raising Efforts
On the funding front, Papyrus secured a $200,000 unsecured loan facility with Irwin Biotech during July, with conversion into shares and attaching options subject to shareholder approval. This loan adds to the company’s existing financing arrangements, including convertible notes and an R&DTI loan facility, which collectively underpin its commercialisation and operational expenditures.
Additionally, Papyrus progressed revised engagement terms with L39 Capital to complete the balance of a previously announced capital raising. The revised program contemplates $700,000 in additional funding split across a $200,000 initial tranche and a further $500,000 loan tranche, with security arrangements pending shareholder consent. These moves reflect a strategic push to secure sufficient cash runway amid ongoing development efforts.
Cash Flow and Operational Spend Reflect Early-Stage Commercialisation
The company reported net cash used in operating activities of $159,000 for July, primarily driven by R&D facility operating costs, staff expenses, and corporate overheads. Investing activities were modest, with $6,000 spent on property, plant, and equipment. Financing activities contributed a net inflow of $346,000, reflecting new borrowings.
At month-end, Papyrus held $426,000 in cash and cash equivalents, including $214,000 restricted funds held by its Egyptian subsidiary. Combined with $447,000 in unused finance facilities, the company estimates approximately 5.5 months of funding available at the current burn rate. While below the six-month benchmark, management expects to maintain operating cash flows and continue raising capital successfully based on prior experience.
Outlook Hinges on Trial Outcomes and Funding Execution
Papyrus’s trajectory remains focused on incorporating trial learnings into product development and advancing toward commercial-scale production under the TBS contract. The company’s funding strategy, including the Irwin Biotech loan and L39 Capital capital raising, will be crucial to sustaining this progress. Shareholder approval for certain financing conversions will be a key upcoming milestone.
Bottom Line?
Papyrus is navigating the delicate balance of refining its biodegradable board product while securing vital funding, with its next TBS sample run and capital raising outcomes set to shape its commercialisation momentum.
Questions in the middle?
- Will the additional TBS sample run resolve the performance gaps identified in the initial trial?
- How swiftly can Papyrus secure shareholder approval for loan conversions and capital raising terms?
- Can the company extend its funding runway beyond 5.5 months to support scaling efforts?